What is DTCFF's current stock price?

DTCFF (Defence Therapeutics Inc.) is currently trading at $0.45 with a market cap of $26.3M.

What sector is Defence Therapeutics Inc. in?

Defence Therapeutics Inc. (DTCFF) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

Back to Market返回行情

DTCFF Defence Therapeutics Inc.

OTCHealthcare

$0.4459+15.01%ClosedMarket Cap: $26.3M

As of 2026-05-29 16:00

Latest News

Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of DirectorsNewsfile Corp · 2026-06-01

Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis MeterissianNewsfile Corp · 2026-05-29

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing CapabilitiesNewsfile Corp · 2026-05-19

Defence Therapeutics Announces Grant of Restricted Stock UnitsNewsfile Corp · 2026-04-24

Defence Therapeutics Announces Warrant Terms AmendmentNewsfile Corp · 2026-03-20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

OTC

Beta

1.39

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.